{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:19:02Z","timestamp":1769152742007,"version":"3.49.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012320","name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After the reports of\u00a0severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, patients who had received one dose of ChAdOx1-S-nCoV-19 vaccine were recommended a second dose of Pfizer\u2019s BNT162b2 vaccine. In hemodialysis patients, we compared the humoral immunogenicity and tolerability of homologous vaccination with ChAdOx1-nCoV-19\/ChAdOx1-nCoV-19 (ChAd\/ChAd) and BNT162b2\/BNT162b2 (BNT\/BNT) with heterologous vaccination of first dose of ChAdOx1-nCoV-19 and a second dose with BNT162b2 (ChAd\/BNT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multicenter prospective observational study, SARS-CoV-2 spike-IgG antibody levels, Nucleocapsid-protein-IgG-antibodies, and vaccine tolerability were assessed 6 weeks after second SARS-CoV-2 vaccination in 137 hemodialysis patients and 24 immunocompetent medical personnel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In COVID-19-na\u00efve hemodialysis patients, significantly higher median SARS-CoV-2-spike IgG levels were found after ChAd\/BNT (N\u2009=\u200916) compared to BNT\/BNT (N\u2009=\u2009100) or ChAd\/ChAd (N\u2009=\u200910) (1744 [25th\u201375th percentile 276\u20132840] BAU\/mL versus 361 [25th\u201375th percentile 120\u2013936] BAU\/mL; p\u2009=\u20090.009; 1744 [25th\u201375th percentile 276\u20132840] BAU\/mL versus 100 [25th\u201375th percentile 41\u2013346] BAU\/mL; p\u2009=\u20090.017, respectively). Vaccinated, COVID-19-na\u00efve medical personnel had median SARS-CoV-2 spike-IgG levels of 650 (25th\u201375th percentile 217\u20131402) BAU\/mL and vaccinated hemodialysis patients with prior COVID-19 7047 (25th\u201375th percentile 685\u201310,794) BAU\/mL (N\u2009=\u200911). In multivariable regression analysis, heterologous vaccination (ChAd\/BNT) of COVID-19-na\u00efve hemodialysis patients was independently associated with SARS-CoV-2 spike-IgG levels. The first dose of ChAd and the second dose of BNT after the first vaccination with ChAd (heterologous vaccination, ChAd\/BNT) were associated with more frequent but manageable side effects compared with homologous BNT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within the limitations of this study, heterologous vaccination with ChAd\/BNT appears to induce stronger humoral immunity and more frequent but manageable side effects than homologous vaccination with BNT\/BNT or with ChAd\/ChAd in COVID-19-na\u00efve hemodialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01247-7","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T01:02:43Z","timestamp":1643245363000},"page":"1467-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Humoral immunogenicity and tolerability of heterologous ChAd\/BNT compared with homologous BNT\/BNT and ChAd\/ChAd SARS-CoV-2 vaccination in hemodialysis patients"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-7416","authenticated-orcid":false,"given":"Michael","family":"Haase","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3001-5257","authenticated-orcid":false,"given":"Paul","family":"Lesny","sequence":"additional","affiliation":[]},{"given":"Mark","family":"Anderson","sequence":"additional","affiliation":[]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Stec","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6881-2249","authenticated-orcid":false,"given":"Anja","family":"Haase-Fielitz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-6356","authenticated-orcid":false,"given":"Mathias","family":"Haarhaus","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Santos-Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Pedro Mota","family":"Veiga","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Macario","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck RW Jr, Klein NP, Kitchin N et al (2021) Safety, Immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 385:239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2107456","journal-title":"N Engl J Med"},{"key":"1247_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"1247_CR3","doi-asserted-by":"publisher","first-page":"e1397","DOI":"10.1093\/cid\/ciab397","volume":"73","author":"G Haidar","year":"2021","unstructured":"Haidar G, Mellors JW (2021) Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis 73:e1397\u2013e1401. https:\/\/doi.org\/10.1093\/cid\/ciab397","journal-title":"Clin Infect Dis"},{"key":"1247_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nefro.2015.10.013","volume":"36","author":"R Garc\u00eda Agudo","year":"2016","unstructured":"Garc\u00eda Agudo R, Aoufi Rabih S, Barril Cuadrado G et al (2016) Spanish multicentre PIBHE study: prevalence and immunization of chronic hepatitis B in haemodialysis patients in Spain. Nefrologia 36:126\u2013132. https:\/\/doi.org\/10.1016\/j.nefro.2015.10.013","journal-title":"Nefrologia"},{"key":"1247_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3238\/arztebl.m2021.0160","volume":"118","author":"E Hoxha","year":"2021","unstructured":"Hoxha E, Suling A, Turner JE et al (2021) COVID-19 prevalence and mortality in chronic dialysis patients. Dtsch Arztebl Int 118:195\u2013196. https:\/\/doi.org\/10.3238\/arztebl.m2021.0160","journal-title":"Dtsch Arztebl Int"},{"key":"1247_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/ckj\/sfab037","volume":"14","author":"M Haarhaus","year":"2021","unstructured":"Haarhaus M, Santos C, Haase M et al (2021) Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings. Clin Kidney J 14:805\u2013813. https:\/\/doi.org\/10.1093\/ckj\/sfab037","journal-title":"Clin Kidney J"},{"key":"1247_CR7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1681\/ASN.2021050611","volume":"32","author":"S Anand","year":"2021","unstructured":"Anand S, Montez-Rath M, Han J et al (2021) Antibody response to COVID-19 vaccination in patients receiving dialysis. J Am Soc Nephrol 32:2435\u20132438. https:\/\/doi.org\/10.1681\/ASN.2021050611","journal-title":"J Am Soc Nephrol"},{"key":"1247_CR8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.kint.2021.04.008","volume":"99","author":"RE Billany","year":"2021","unstructured":"Billany RE, Selvaskandan H, Adenwalla SF et al (2021) Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms. Kidney Int 99:1492\u20131494. https:\/\/doi.org\/10.1016\/j.kint.2021.04.008","journal-title":"Kidney Int"},{"key":"1247_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.02.21261516","author":"P Garcia","year":"2021","unstructured":"Garcia P, Anand S, Han J et al (2021) COVID19 vaccine type and humoral immune response in patients receiving dialysis. medRxiv. https:\/\/doi.org\/10.1101\/2021.08.02.21261516","journal-title":"medRxiv"},{"key":"1247_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/ckj\/sfab059","volume":"14","author":"M Giot","year":"2021","unstructured":"Giot M, Robert T, Brunet P, Resseguier N, Lano G (2021) Vaccination against COVID-19 in a haemodialysis centre: what is the risk of bleeding complications? Clin Kidney J 14:1701\u20131703. https:\/\/doi.org\/10.1093\/ckj\/sfab059","journal-title":"Clin Kidney J"},{"key":"1247_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab293","author":"C Santos-Ara\u00fajo","year":"2021","unstructured":"Santos-Ara\u00fajo C, Veiga PM, Santos MJ et al (2021) Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in hemodialysis patients: a multicenter study. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab293","journal-title":"Nephrol Dial Transplant"},{"key":"1247_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu X, Shaw RH, Stuart ASV et al (2021) Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398:856\u2013869. https:\/\/doi.org\/10.1016\/S0140-6736(21)01694-9","journal-title":"Lancet"},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins J, Hammerschmidt SI, Cossmann A et al (2021) Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat Med 27:1525\u20131529. https:\/\/doi.org\/10.1038\/s41591-021-01449-9","journal-title":"Nat Med"},{"key":"1247_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00357-X","author":"D Hillus","year":"2021","unstructured":"Hillus D, Schwarz T, Tober-Lau P et al (2021) Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(21)00357-X","journal-title":"Lancet Respir Med"},{"key":"1247_CR15","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","volume":"397","author":"RH Shaw","year":"2021","unstructured":"Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD (2021) Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 397:2043\u20132046","journal-title":"Lancet"},{"key":"1247_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495\u20131499. https:\/\/doi.org\/10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"key":"1247_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40620-021-01076-0","volume":"34","author":"P Lesny","year":"2021","unstructured":"Lesny P, Anderson M, Cloherty G et al (2021) Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. J Nephrol 34:975\u2013983. https:\/\/doi.org\/10.1007\/s40620-021-01076-0","journal-title":"J Nephrol"},{"key":"1247_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/biomet\/63.3.655","volume":"63","author":"R Markus","year":"1976","unstructured":"Markus R, Peritz E, Gabriel KR (1976) On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655\u2013660","journal-title":"Biometrika"},{"key":"1247_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/sim.4780100609","volume":"10","author":"P Bauer","year":"1991","unstructured":"Bauer P (1991) Multiple testing in clinical trials. Stat Med 10:871\u2013890. https:\/\/doi.org\/10.1002\/sim.4780100609","journal-title":"Stat Med"},{"key":"1247_CR20","doi-asserted-by":"publisher","first-page":"S0085-2538(21)0","DOI":"10.1016\/j.kint.2021.10.006","volume":"14","author":"T Davidovic","year":"2021","unstructured":"Davidovic T, Schimpf J, Abbassi-Nik A et al (2021) Waning humoral response six months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients-time for a boost. Kidney Int 14:S0085-2538(21)00942-X42. https:\/\/doi.org\/10.1016\/j.kint.2021.10.006","journal-title":"Kidney Int"},{"key":"1247_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100249","volume":"11","author":"P Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A (2021) Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur 11:100249. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100249","journal-title":"Lancet Reg Health Eur"},{"key":"1247_CR22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021010104","author":"P Garcia","year":"2021","unstructured":"Garcia P, Montez-Rath ME, Moore H et al (2021) SARS-CoV-2 vaccine acceptability in patients on hemodialysis: A nationwide survey. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.2021010104","journal-title":"J Am Soc Nephrol"},{"key":"1247_CR23","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/j.ekir.2021.08.030","volume":"6","author":"S Blanchi","year":"2021","unstructured":"Blanchi S, Torreggiani M, Chatrenet A et al (2021) COVID-19 Vaccine hesitancy in patients on dialysis in Italy and France. Kidney Int Rep 6:2763\u20132774. https:\/\/doi.org\/10.1016\/j.ekir.2021.08.030","journal-title":"Kidney Int Rep"},{"key":"1247_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.kint.2021.06.025","volume":"100","author":"D Ducloux","year":"2021","unstructured":"Ducloux D, Colladant M, Chabannes M et al (2021) Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int 100:702\u2013704","journal-title":"Kidney Int"},{"key":"1247_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2215\/CJN.04080321","volume":"16","author":"L Chan","year":"2021","unstructured":"Chan L, Fuca N, Zeldis E, Campbell KN, Shaikh A (2021) Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19. Clin J Am Soc Nephrol 16:1258\u20131260","journal-title":"Clin J Am Soc Nephrol"},{"key":"1247_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04120-y","author":"B Pozzetto","year":"2021","unstructured":"Pozzetto B, Legros V, Djebali S et al (2021) Immunogenicity and efficacy of heterologous ChadOx1\/BNT162b2 vaccination. Nature. https:\/\/doi.org\/10.1038\/s41586-021-04120-y","journal-title":"Nature"},{"key":"1247_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.721286","volume":"8","author":"C Speer","year":"2021","unstructured":"Speer C, Morath C, T\u00f6llner M et al (2021) Humoral responses to single-dose BNT162b2 mRNA vaccination in dialysis patients previously infected with SARS-CoV-2. Front Med (Lausanne) 8:721286. https:\/\/doi.org\/10.3389\/fmed.2021.721286","journal-title":"Front Med (Lausanne)"},{"key":"1247_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19741","volume":"4","author":"M Anderson","year":"2021","unstructured":"Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J (2021) SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open 4:e2119741. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.19741","journal-title":"JAMA Netw Open"},{"key":"1247_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/medicina57070732","volume":"57","author":"K Polewska","year":"2021","unstructured":"Polewska K, Tylicki P, Biedunkiewicz B et al (2021) Safety and tolerability of the BNT162b2 mRNA COVID-19 vaccine in dialyzed patients. COViNEPH Project Medicina (Kaunas) 57:732. https:\/\/doi.org\/10.3390\/medicina57070732","journal-title":"COViNEPH Project Medicina (Kaunas)"},{"key":"1247_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0140-6736(21)01854-7","volume":"398","author":"EJ Carr","year":"2021","unstructured":"Carr EJ, Wu M, Harvey R et al (2021) Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet 398:1038\u20131041. https:\/\/doi.org\/10.1016\/S0140-6736(21)01854-7","journal-title":"Lancet"},{"key":"1247_CR31","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1093\/ckj\/sfab152","volume":"14","author":"M Dekervel","year":"2021","unstructured":"Dekervel M, Henry N, Torreggiani M et al (2021) Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J 14:2349\u20132355","journal-title":"Clin Kidney J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01247-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01247-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01247-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:45:39Z","timestamp":1767685539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40620-022-01247-7"}},"subtitle":["A multicenter prospective observational study"],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01247-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MiH, PL, MaH, CSA, PMV, and FM are employees of Diaverum, and MA, GC, and MS are employees of Abbott Laboratories (IL, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Ethics Committee of the <i>\u2018Landes\u00e4rztekammer Brandenburg\u2019<\/i>, Germany (registry number S 9\/(bB)\/2021). Approval was obtained from the Ethics Committee of the \u2018<i>Landes\u00e4rztekammer Brandenburg\u2019<\/i>, Germany (registry number No. S 9\/(bB)\/2021). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to participate was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent to publish was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}